Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Telemedicine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Telemedicine. Displaying page 1 of 1.
    EudraCT Number: 2020-005882-15 Sponsor Protocol Number: CBYL719A03201 Start Date*: 2021-05-12
    Sponsor Name:Novartis Pharma AG
    Full Title: Open-label, multicenter, pilot-trial evaluating the safety and utility of a hybrid decentralized clinical trial (DCT) approach using a TELEmedicine platform in patients with HR-positive/HER2-negati...
    Medical condition: HR-positive/HER2-negative advanced breast cancer with a PIK3CA mutation
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003268-25 Sponsor Protocol Number: AT-03A-017 Start Date*: 2023-05-12
    Sponsor Name:Atea Pharmaceuticals, Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004695-18 Sponsor Protocol Number: RES-Q-HR Start Date*: 2020-12-02
    Sponsor Name:Heinrich-Heine-University Düsseldorf
    Full Title: Reconvalescent plasma/Camostat mesylate early in Sars-CoV-2 Q-PCR positive high risk individuals
    Medical condition: The novel coronavirus designated SARS CoV-2, and the disease caused by this virus designated COVID-19. No treatment is available for early disease stages and non-hospitalized patients to date. This...
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    23.0 100000004848 10084442 SARS-CoV-2 PCR test positive LLT
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000382-41 Sponsor Protocol Number: WA29330 Start Date*: 2015-03-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-blind, double-dummy active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris
    Medical condition: Pemphigus Vulgaris (PV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002878-13 Sponsor Protocol Number: AGO/2016/008 Start Date*: 2016-10-03
    Sponsor Name:Ghent University Hospital
    Full Title: Comparison of continuous infusion versus automated bolus of local anesthetic for postoperative analgesia with popliteal sciatic nerve blockade (nerve catheters) in ambulatory foot surgery.
    Medical condition: Elective foot surgery under sciatic nerve blockade.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10036276 Postoperative analgesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000627-12 Sponsor Protocol Number: CV43140 Start Date*: 2021-06-01
    Sponsor Name:F. Hoffmann La Roche Ltd.
    Full Title: A MULTICENTER, OBSERVATIONAL, 6 MONTH FOLLOW-UP STUDY OF PATIENTS WITH COVID 19 PREVIOUSLY ENROLLED IN A RO7496998 (AT-527) STUDY
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) PT (Prematurely Ended) DK (Completed) DE (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-002360-30 Sponsor Protocol Number: NA-1-009 Start Date*: 2021-01-05
    Sponsor Name:NoNO Inc.
    Full Title: A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Nerinetide in Participants with Acute Ischemic Stroke Under...
    Medical condition: Acute ischemic stroke (AIS)
    Disease: Version SOC Term Classification Code Term Level
    22.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    22.1 10029205 - Nervous system disorders 10055221 Ischemic stroke LLT
    22.1 10029205 - Nervous system disorders 10023027 Ischaemic stroke NOS LLT
    22.1 10029205 - Nervous system disorders 10074321 Nonhaemorrhagic stroke LLT
    22.1 10029205 - Nervous system disorders 10074318 Nonhemorrhagic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005759-18 Sponsor Protocol Number: CV43043 Start Date*: 2021-05-10
    Sponsor Name:F. Hoffmann La Roche Ltd.
    Full Title: A MULTICENTER, PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OUTPATIENT STUDY TO EVALUATE THE EFFICACY, SAFETY, AND ANTIVIRAL ACTIVITY OF RO7496998 AT-527 IN PATIENTS WITH MILD OR MODERAT...
    Medical condition: Mild to Moderate coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) DK (Prematurely Ended) FR (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003434-24 Sponsor Protocol Number: ACP-103-034 Start Date*: 2017-04-28
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) CZ (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003436-20 Sponsor Protocol Number: ACP-103-038 Start Date*: 2017-04-28
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) ES (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005598-28 Sponsor Protocol Number: ADG20PREV001 Start Date*: 2021-09-17
    Sponsor Name:Adagio Therapeutics Inc
    Full Title: A Phase 2/3 Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE)
    Medical condition: The prevention of symptomatic coronavirus (CoV) disease 2019 (COVID 19) in adults and adolescents
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084529 2019 novel coronavirus infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PL (Prematurely Ended) CZ (Completed) BG (Completed) RO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003437-18 Sponsor Protocol Number: ACP-103-039 Start Date*: 2017-10-05
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (Enhance-2)
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000269-34 Sponsor Protocol Number: GC2010 Start Date*: 2021-03-20
    Sponsor Name:Grifols Therapeutics LLC
    Full Title: A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of Anti-COVID-19 Immune Globulin (Human) 20% (C19-IG 20%) versus Placebo in Asymptomatic Ambulatory...
    Medical condition: Subjects with laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by qualitative PCR (reverse transcriptase [RT]-PCR) that are asymptomathic
    Disease: Version SOC Term Classification Code Term Level
    23.0 10022891 - Investigations 10084271 SARS-CoV-2 test positive PT
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    23.0 100000004862 10084467 Asymptomatic SARS-CoV-2 infection LLT
    23.1 100000004862 10084529 2019 novel coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003690-21 Sponsor Protocol Number: R10933-10987-COV-2067 Start Date*: 2020-10-06
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS CoV 2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with COVID-19
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-003343-29 Sponsor Protocol Number: ACP-103-064 Start Date*: 2019-11-15
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE 2)
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) HU (Completed) BG (Completed) ES (Ongoing) LT (Completed) IT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2020-006082-11 Sponsor Protocol Number: ADG20-TRMT-001 Start Date*: 2021-06-02
    Sponsor Name:Adagio Therapeutics Inc.
    Full Title: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP)
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) DE (Prematurely Ended) HU (Completed) BG (Prematurely Ended) PL (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-003199-11 Sponsor Protocol Number: 2013-1 Start Date*: 2015-09-25
    Sponsor Name:GETAID - Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives
    Full Title: Changing the coUrse of cRohn's disease with an Early use of adalimumab: The CURE study.
    Medical condition: Crohn's disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 01:20:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA